Drugs / SQP33
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04106492 | Aug 2020 → Sep 2023 | cancer | Shasqi, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-05-31 | Shasqi, Inc. | Results Shasqi to Present Updated Clinical Data on SQ3370 at the 2022 ASCO Annual Meeting shasqi.com ↗ |
| 2021-01-27 | Shasqi, Inc. | Results Shasqi Announces Publication of Preclinical Data Demonstrating Proof-of-Principle for Click-Activated Approach to Cancer Treatment shasqi.com ↗
These studies rendered the protodrug of doxorubicin, SQP33, as the most promising candidate for in vivo studies. |
| 2021-01-05 | Shasqi, Inc. | Results Click Activated Protodrugs Against Cancer Increase the Therapeutic Potential of Chemotherapy through Local Capture and Activation shasqi.com ↗
In vitro evaluation of cytotoxicity, solubility, stability and activation rendered the protodrug of doxorubicin, SQP33, as the most promising candidate for in vivo studies. |
| 2020-06-22 | Shasqi, Inc. | Results Shasqi Demonstrates Chemistry-based Platform Produces Local and Systemic Anti-tumor Response in Preclinical Cancer Model shasqi.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SQP33 | “SQ3370 consists of a tumor-localizing biopolymer (SQL70) and a chemically-attenuated doxorubicin (Dox) protodrug SQP33; the protodrug is activated upon clicking with the...” PMID 37034617 ↗ Mar 2023 |
| Modality | Other / unclassified | “a chemically-attenuated doxorubicin (Dox) protodrug SQP33” PMID 37034617 ↗ Mar 2023 |
| Route | Intravenous | “5 daily intravenous doses of SQP33 protodrug” PMID 37034617 ↗ Mar 2023 |